menu
    • menu

    Company profile for Antabio

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. All Antabio programs address WHO critical priority pathogens and are eligible for streamlined development. Antabio has built a best in class, international team with highly successful track records including former executives from Novexel, Galapagos, Merck, GSK and ...
    Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. All Antabio programs address WHO critical priority pathogens and are eligible for streamlined development. Antabio has built a best in class, international team with highly successful track records including former executives from Novexel, Galapagos, Merck, GSK and Astra Zeneca. Antabio’s lead program MBLI (expected to enter the clinic in 2020) addresses a critical global threat that is already highly prevalent in Asia-Pacific.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AntabioFrance Flag
    Country
    Country
    France
    Address
    Address
    436 Rue Pierre et Marie Curie 31670 Labège
    Telephone
    Telephone
    +33 5 31 47 18 57
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://antabio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Antabio on quest to tackle antibiotic resistance
    Antabio on quest to tackle antibiotic resistance

    26 May 2023

    // Phalguni Deswal CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/antabio-on-quest-to-tackle-antibiotic-resistance/

    Phalguni Deswal CLINICAL TRIALS ARENA
    26 May 2023
    Share Share
    Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310
    Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310

    25 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/25/2675962/0/en/Antabio-Announces-First-Subjects-Dosed-in-Phase-1-Clinical-Trial-of-MEM-ANT3310-a-Highly-Differentiated-Antibiotic-for-Severe-Hospital-Infections.html

    GLOBENEWSWIRE
    25 May 2023
    Share Share
    Antabio Receives QIDP Designation From the USFDA for the Dev of MEM-ANT3310
    Antabio Receives QIDP Designation From the USFDA for the Dev of MEM-ANT3310

    05 May 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antabio-receives-qidp-designation-from-the-us-fda-for-the-development-of-mem-ant3310-a-novel-broad-spectrum-combination-therapy-targeting-whos-priority-pathogens-301053387.html

    PR NEWSWIRE
    05 May 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search